[Methodology of the inquiry MISSION (menopause, breast cancer risk, morbidity and prevalence)].
OBJECTIVE
The ambition of this article is to detail and to explain the methodology of the study named MISSION (Menopause: breast cancer risk, morbidity and prevalence). The aims of MISSION are to determine the prevalence of breast cancer and global morbidity in France among menopausal women treated or not with hormone replacement therapy (HRT) and followed by a gynecologist.


METHODS
6600 menopausal women [3300 with HRT -- ie for estrogen: only estradiol via oral or transdermal administration; for progestogen: natural progesterone or assimiled or one pregnane derived (excluding medroxyprogesterone acetate) or non-pregnane derived -- and 3300 without HRT] will be enrolled in France between January 5 2004 and February 28 2005 by 825 gynecologists, members or not of the National Federation of Medical Gynecologists (FNCGM). This study design is a historico-prospective with case randomization. MISSION is conducted by a Theramex-Merck Laboratories initiative in collaboration with a WHO (World Health Organization) Collaborating Center for Public Health Aspects of Rheumatic Diseases and a multidisciplinary expert group.


CONCLUSIONS
First results of this study will contribute to better knowledge of women health.
Chevallier
T
T
Laboratoire de Biostatistique, d'Epidémiologie et de Recherche Clinique, IURC, Montpellier.
Daurès
J-P
JP
Micheletti
M-C
MC
Reginster
J-Y
JY
D001943:Breast Neoplasms / Q000453:epidemiology* / Q000401:mortality*; D015331:Cohort Studies; D015914:Estrogen Replacement Therapy; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D008593:Menopause; D015995:Prevalence; D012107:Research Design; D012307:Risk Factors